Rapid Dose Therapeutics Corp. (RDT) (
CSE.DOSE,
OTCMKTS: RDTCF,
Forum) – a Canadian biotechnology company revolutionizing drug delivery through innovation – has entered into an agreement with Oakland Health Ltd. (operating as “RD Therapeutics”) to supply
QuickStrip™ products to the United Kingdom and the European Union.
Mark Upsdell, CEO of Rapid Dose Therapeutics, commented:
“This strategic partnership supports our business plan of rapid global expansion, bringing our novel QuickStrip™ technology and nutraceutical products into the United Kingdom, with further expansion plans throughout the European Union. It is as a result of our strategic partnerships with leading organizations such as RD Therapeutics that we will achieve broader awareness of our novel delivery technology, as it becomes more widely used, including as an oral delivery system for vaccines.
Full story
here.
About Rapid Dose Therapeutics
Rapid Dose Therapeutics Corp. is a publicly-traded Canadian Life Sciences company providing innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. RDT’s service-based annuity contracts drive recurring revenue and facilitate rapid expansion into emerging markets across multiple consumer segments. RDT is committed to continually create innovative solutions for humans, animals, and plants.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.
FULL DISCLOSURE: Rapid Dose Therapeutics Corp. is a client of Stockhouse Publishing.